International Conference on
Stem Cell
Scientific Program
Joel I. Osorio
Regenerage Clinic
Biography:
Joel I. Osorio is a MD, CEO and Founder of Biotechnology and Regenerative Medicine at RegenerAge™
(www.regenerageclinic.com). He is Vice President of International Clinical Development for Bioquark,
Inc. (www.bioquark.com) and Founder and president for the Dr. Jois A.C initiative (www.drjois.com)
Advance Fellow by the American Board of Anti-Aging and Regenerative Medicine (A4M), Visiting
Scholar at University of North Carolina at Chapel Hill (Dermatology). He is a f ellow in Stem Cell
Medicine by the American Academy of Anti-Aging Medicine.
Abstract
A complete spinal cord injury (SCI) is the complete sensory and motor loss below the site of spinal
cord injury following acute or chronic destruction, compression, or ischemia of the spinal cord. It constitutes
an inestimable public health issue. The most crucial phase in the pathophysiological process of SCI concerns
the well-known secondary injury, which is the uncontrolled and destructive cascade occurring later with
aberrant molecular signaling, inflammation, vascular changes, and secondary cellular dysfunctions. The use
of our combinatorial biologics based in the combination of a unique polypeptide (Bioquantine®) and
Wharton’s Jelly or Umbilical Cord Mesenchymal Stem Cells (UCMSCs) specifically Wharton’s Jelly
derivate ones represents one of the most important and promising and now safe and tested strategy to
stimulate the neuroregeneration. This combinatorial method attract, among the other sources and types of
stem cells, increased because of their ease of isolation/preservation and their properties. In this review, the
therapeutic role of MSCs is discussed, together with their properties, application, limitations, and future
perspectives. However, despite our deeper understanding of the molecular changes occurring after initial
insult to the spinal cord, the cure for paralysis remains elusive. The current treatment of SCI is limited to
early administration of high dose steroids to mitigate the harmful effect of cord edema that occurs after SCI
and to reduce the cascade of secondary delayed SCI. An array of mesenchymal stem cells (MSCs) from
various sources with novel and promising strategies are being developed to improve function after SCI. In
this review, we briefly discuss the pathophysiology of spinal cord injuries and characteristics and the
potential sources of MSCs that can be used in the treatment of SCI. Our evidence and science based method
(as we previously demonstrated with a patient 2 years ago) is showing a promising alternative on the ASIAA
classification SCI. Added to it, we utilized an improved delivery method (making it ambulatory) for the in
situ application of subdural Whaton’s Jelly MSCs and a unique polypeptide (Bioquantine®). Thereafter we
proceeded with the intrathecal application of an advanced neurostimulator biomedical system obtaining
improved results and faster clinical recovery after only 5 weeks of the started translational protocol.
Keywords: mesenchymal stem cells, umbilical cord derived mesenchymal stem cells, Wharton’s jelly
mesenchymal cells, polypeptide, Bioquantine®, spinal cord injury, neurostimulator system, regenerative
medicine, translational medicine.
Learning Objectives:
- Demonstrate new medical pathways for a possible neuroregeneration.
- Demonstrate the safe use of our combinatorial biologics.
- Demonstrate the use and efficacy of Wharton’s Jelly mesenchymal stem cells.
- Demonstrate the safe and efficacy of and advanced neurostimulator biomedical system.
- Demonstrate the efficacy of therapies of regenerative medicine and interventionist pain and palliative care
management.
Topic description:
Spinal cord injury (SCI) constitutes an inestimable public health issue, with an incidence of 40–80 per
million people per year and continues to be a devastating injury to affected individuals and their families and
exacts an enormous financial, psychological and emotional cost to them and to society. Our innovative
translational medical protocol is based in science and regenerative medicine and can bring another option to
those known as “No Option” patients
The differentiation and regeneration potential of stem cells has been well studied in both preclinical and
clinical investigations. A traumatic spinal cord injury triggers a complex local inflammatory reaction capable
of enhancing repair and exacerbating pathology [Fig. 1]. Spinal cord injury (SCI) constitutes an inestimable
public health issue, with an incidence of 40–80 per million people per year. Wharton’s jelly mesenchymal
stem cells (MSCs) and showed hopeful promise in preclinical research.
- Stem Cell Research
- Stem Cell Treatment
- Pluripotent Stem Cell-Based Cancer Therapy
- Cardiac Stem Cell Therapeutics
- Somatic Cell Therapy
- Neural Stem Cells Therapy
- Stem Cell Technologies
- Tissue Engineering
- Applications of Tissue Engineering
- Immunotherapy
